DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)
AmerisourceBergen, a global healthcare solutions leader, today announced that US Bioservices, an independent specialty pharmacy, has been selected by Emmaus Medical, Inc. as the specialty pharmacy for EndariTM (L-glutamine oral powder), for the treatment of patients with sickle cell disease.
The U.S. Food and Drug Administration approved Endari on July 7, 2017 for adult and pediatric patients 5 years of age and older to reduce acute complications of sickle cell disease. Endari is the first approved treatment for sickle cell disease in pediatric patients and the first new treatment available in nearly 20 years for adults.
As part of this partnership, Emmaus will leverage the breadth of AmerisourceBergen’s integrated commercialization solutions to support adherence and realize the best possible outcomes for patients. In addition to utilizing the comprehensive clinical services of US Bioservices, Emmaus will also collaborate with AmerisourceBergen’s ASD Healthcare and ICS.
education & researchPediatric Residents’ Perceived Barriers to Opioid Use in Sickle Cell Disease Pain ManagementObjective: Current guidelines recommend...
news & eventsGene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
education & researchTranscutaneous electrical nerve stimulation (TENS) for pain management in sickle cell diseaseAs defined by the American Physical Ther...
news & eventsNovo Nordisk obtains licence for sickle cell disease programNovo Nordisk inked a global licence deal...
news & eventsStudy Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
news & eventsIn A 1st, Doctors In U.S. Use CRISPR Tool To Treat Patient With Genetic DisorderFor the first time, doctors in the U.S. ...
videos & visualsBlood Transfusions: How, Why, and When? (Part 1)https://www.youtube.com/watch?v=KRjjp0Jw...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.